FY2025 · ended Dec 31, 2025 · Revenue $154.90M, +7.4% YoY · Filed Feb 26, 2026
Heron Therapeutics, Inc. /DE/ (HRTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $154.9 million and a net loss of $20.2 million. Free cash flow was -$27.9 million. As of Jun 30, 2026 it held $42.7 million in cash and investments and $5.7 million in total debt.
Revenue (TTM)
$151.18M
+1.0% vs year-ago TTM
Net income (TTM)
$-34.05M
-3557.3% vs year-ago TTM
Operating cash flow (TTM)
$-11.61M
+58.8% vs year-ago TTM
Free cash flow (TTM)
$-12.13M
+58.9% vs year-ago TTM
EPS (TTM)
$-0.21
-3832.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
188.54M
+23.8% vs prior year
Net cash
$36.96M
as of Jun 30, 2026
Operating margin
-7.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 818033
- Former names
- AP PHARMA INC /DE/ (until Jan 7, 2014); ADVANCED POLYMER SYSTEMS INC /DE/ (until Apr 6, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M |
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M | -$217.8M |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M |
| Diluted EPS | -$0.12 | -$0.09 | -$0.80 | -$1.67 | — |
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M |
| Free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M | -$206.4M |
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M |
| Stockholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M |
| Cash and investments | $46.6M | $59.3M | $80.4M | $84.9M | $157.6M |
| Total debt | $0 | $3.0M | $5.9M | $8.2M | $10.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Listing notice
|
Jun 25, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
All 1000 Heron Therapeutics, Inc. /DE/ SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.